13 research outputs found
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure</p
Supplementary Table 1 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
List of key reagents</p
Supplementary Table 2 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Table comparing various key pharmacokinetic parameters (Assay, left column) between C-91 and C-86.</p
Supplementary Figure S4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure</p
Supplementary Table 4 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Plasma pharmacokinetic comparisons of C86, C91, and C99 in mice for parameters outlined in the table.</p
Supplementary Table 5 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Tissue pharmacokinetics and bio-distribution of C86 at two different does through the intraperitoneal route.</p
Supplementary Figure S6 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure</p
Supplementary Data Legends from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Legends for supplementary figures and tables.</p
Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Supplementary Figure</p
Supplementary Table 3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma
Safetyscreen assay for C86 performed at eurofins.</p